ReviewCurrent rheumatology reports2026
Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.
Review in Current rheumatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSystemic lupus erythematosus (SLE) patients are complex with multisystem organ involvement and often organ damage due to the disease and its treatment. This review aims to shed light on surgical outcomes in SLE patients and how these can be optimized in the perioperative setting. RECENT
findingsSLE patients often require various surgical procedures as a direct result of their disease. Several studies, the majority orthopedic, have reported the often-increased incidence of infectious, thrombotic, hemorrhagic and other postoperative outcomes in SLE patients compared to controls, as well as the role of lupus activity, severity, comorbidities, and glucocorticoids (GC) in predicting poor outcomes. Unfortunately, most publications are limited by retrospective design, small numbers or lack of granular information on lupus activity and its treatment. Nevertheless, recent guidelines for the treatment of SLE and the perioperative management of immunosuppressive therapies (IST) in patients with rheumatic diseases undergoing hips/knee arthroplasty have been published and have filled an important gap in the management of these patients. Achievement of remission or low lupus activity by escalating IST and GC taper to prednisone doses ≤ 5-7.5 mg/day is recommended in general and in the perioperative setting. Severe SLE patients actively treated for organ involvement may be allowed to continue IST perioperatively, but others may withhold IST. Careful multidisciplinary planning of elective surgeries, considering disease activity, severity, and comorbidities, as well as prudent perioperative GC, IST and anticoagulant management, should optimize outcomes in SLE patients. Large prospective studies of SLE patients undergoing common surgeries should facilitate further progress.
Indexed as
Identifiers
42105130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.